IM-PROVE I: Rapid loss followed by transient increases in HBV RNA in chronic hepatitis B subjects during treatment with imdusiran and pegylated interferon alfa-2a is associated with HBsAg seroclearance
Recommended Citation
Espiritu CL, Eley T, Gray K, Anderson M, Fortney T, Cloherty G, Medvedeva E, Yuen M, Heo J, Nahass RG, Lai-Hung Wong G, Burda T, Bhamidimarri K, Hu T, Nguyen TT, Lim Y, Chen C, Gordon SC, Holmes J, Chuang W, Kohli A, Alkhouri N, Lam AM, Sofia MJ, Sims KD, Thi EP. IM-PROVE I: Rapid loss followed by transient increases in HBV RNA in chronic hepatitis B subjects during treatment with imdusiran and pegylated interferon alfa-2a is associated with HBsAg seroclearance. J Hepatol 2025; 82:S832-S833.
Document Type
Conference Proceeding
Publication Date
5-1-2025
Publication Title
J Hepatol
Abstract
Background and aims: Functional cure (FC) of chronic hepatitis B (CHB) requires suppression of viral replication, reduction of HBV antigens and induction of anti-HBV immune responses. Imdusiran (IDR) is a N-Acetylgalactosamine–conjugated, pan-genotypic small interfering RNA therapeutic that blocks all HBV RNA transcripts, including HBV X protein, resulting in suppression of viral replication and all viral antigens. IM-PROVE I is an ongoing Phase 2a study assessing 24 weeks (W) of IDR lead-in followed by 12W or 24W of pegylated interferon alfa-2a (IFN) with or without additional IDR doses in 43 nucleos(t)ide analogue (NA) treated CHB subjects. Exploratory HBV biomarker profiles of subjects who achieved FC are compared to subjects who did not achieve FC but who had HBV DNA
Volume
82
First Page
S832
Last Page
S833
